Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 117

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 117
---
 the first day of the month next following the 36-month anniversary of the Commencement Date; |

| • | the date on which the Selling Shareholder shall have purchased the Commitment Amount; |

| • | the 90th day after the date on which, pursuant to or within the meaning of any bankruptcy law, we commence                            
 a voluntary case or any person commences a proceeding against us, in each case that is not discharged or dismissed prior to such 90th 
 day; and                                                                                                                              |

| • | the date on which, pursuant to or within the meaning of any bankruptcy law, a custodian is appointed for              
 us or for all or substantially all of our property, or we make a general assignment for the benefit of our creditors. |

We have the right to terminate
the Purchase Agreement at any time after Commencement Date, at no cost or penalty, upon one business day’s prior written notice
to the Selling Shareholder, subject to us satisfying all existing obligations related to any Depositary Shares issued to the Selling Shareholder
prior to the date of termination. We or the Selling Shareholder may also terminate the Purchase Agreement at the close of business on
the one year anniversary of the signing of the Purchase Agreement or thereafter, in the event the Commencement Date shall not have occurred
prior to such one year anniversary due to our failure to satisfy the conditions precedent to commencement. We and the Selling Shareholder
may also terminate the Purchase Agreement at any time by mutual written consent. No termination of the Purchase Agreement by us or by
the Selling Shareholder will affect any of our respective rights and obligations under (i) the Purchase Agreement with respect to any
pending Purchase, and both we and the Selling Shareholder have agreed to complete our respective obligations with respect to any such
pending Purchase under the Purchase Agreement, and (ii) the Registration Rights Agreement, which shall survive any termination of the
Purchase Agreement. Further, no termination of the Purchase Agreement will be deemed to release us or the Selling Shareholder from any
liability for intentional misrepresentation or willful breach of the Purchase Agreement, the Registration Rights Agreement or any other
related transaction documents.

Dilutive Issuances and Purchase Price Adjustment

For as long as the Selling
Shareholder owns any of our Depositary Shares, if within three trading days immediately following a Purchase Date, we make certain issues
of our securities and such securities are issued at prices, or the New Issuance Price, less than the prices to be